2019 annual report disclosure curtain will be opened, nearly 80% of pharmaceutical companies are expected to be happy

[pharmaceutical network industry trends] next is the annual report season, and the curtain of annual report disclosure of listed companies will officially open It is reported that as of January 14, 2020, 787 companies in Shanghai and Shenzhen stock markets have disclosed performance forecasts, of which 464 companies have expected full year performance, accounting for 58.96% Among them, in the pharmaceutical industry, 79.63% of the pharmaceutical enterprises that have disclosed the annual performance forecast have a good performance Rundu pharmaceutical: a year-on-year growth of 29.86% On January 10, Rundu pharmaceutical released the 2019 annual performance express The report shows that in 2019, the company's production and operation have achieved good results, sales revenue has continued to grow, and its profitability has further enhanced During the reporting period, the operating revenue reached 1.36 billion yuan, an increase of 310 million yuan or 29.86% compared with 1.04 billion yuan in the same period of last year, mainly due to the increase of sales volume of main products of the company Kailaiying: 25% - 40% year-on-year growth Kailaiying expects to achieve RMB 535-600 million in 2019, a 25% - 40% year-on-year growth The reason for the growth of performance is mainly due to its deep-rooted industry advantages in the field of cdmo On the one hand, the number of orders for clinical projects of the company has steadily increased; on the other hand, with the approval of innovative drug projects served by the company, the project revenue of the company in the commercialization stage has been significantly increased Jiuzhou pharmaceutical industry: a year-on-year growth of 55% - 80% Jiuzhou pharmaceutical industry said that the company's continuous deep-rooted cdmo business has made the company's domestic and foreign market expand rapidly, and the company's API business has been rising steadily It is expected that the company's accumulated net profit in 2019 will increase by 55% - 80% compared with the same period of last year Zhaoyan new drug: a year-on-year increase of 40% ~ 60% 1 in 2020 On August 8, Zhaoyan new drug released the notice of performance increase in 2019 After preliminary calculation by the financial department, it is estimated that the net profit attributable to shareholders of Listed Companies in 2019 will be between 151.67 million yuan and 173.34 million yuan Compared with the same period of last year (statutory disclosure data), it will increase about 43.33 million yuan to 65 million yuan, an increase of about 40% - 60% year on year The company said that the performance increase in the current period was mainly affected by the main business With the increase of domestic investment in drug research and development, the prosperity of cro industry continues to be good, and the company's orders continued to grow steadily, resulting in a good completion of orders in 2019; at the same time, the company expanded its experimental facilities in Suzhou, alleviating the lack of production capacity to a certain extent, and further enhancing its profitability Changchun hi tech: a year-on-year growth of 60% ~ 80% After the closing on January 2, Changchun hi tech released the 2019 annual performance forecast According to the announcement, in 2019, the company's net profit attributable to the parent company is expected to be 1.61 billion yuan to 1.812 billion yuan, a year-on-year increase of 60% to 80%; the basic earnings per share is about 9.32 yuan to 10.48 yuan, and the basic earnings per share of the same period last year is 5.92 yuan For the reasons for the substantial increase in 2019 performance, the company said that there are three main reasons 1 The income of key pharmaceutical enterprises holding shares increased; 2 The settlement income of real estate development projects increased year on year; 3 Major asset restructuring was carried out in 2019 The company completed the acquisition of 29.5% of kinsay pharmaceutical and minority shareholders' equity in November 2019 Therefore, the company consolidated the financial statements of kinsay pharmaceutical according to 99.5% of shareholding ratio in November 2019 Pulo pharmaceutical: a year-on-year increase of 43.02% - 56.52% the performance forecast recently released by pulo pharmaceutical shows that the company is expected to make a profit of 530 million yuan – 580 million yuan in 2019, an increase of 43.02% - 56.52% over the same period of last year The main reason is the year-on-year growth of operating revenue and gross profit in the current period Fuxiang shares: a year-on-year increase of 55% - 75% the 2019 performance forecast disclosed by Fuxiang shares shows that the company's net profit attributable to shareholders of Listed Companies in the reporting period is 300 million yuan – 340 million yuan, an increase of 55% - 75% over the same period of last year According to the announcement, there are two reasons for the change in performance On the one hand, during the reporting period, the market demand for the company's main products kept stable growth, and the market orders were regulated to keep increasing; on the other hand, from January to December 2019, the non recurring profit and loss attributable to the shareholders of the listed company was about 2.1 million yuan, which had little impact on the company's profits.